相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。SHP2 tyrosine phosphatase stimulates CEBPA gene expression to mediate cytokine-dependent granulopoiesis
Li Zhang et al.
BLOOD (2011)
Differential biological activity of disease-associated JAK2 mutants
Haiying Zou et al.
FEBS LETTERS (2011)
Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
Animesh Pardanani et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
Fabio P. S. Santos et al.
BLOOD (2010)
Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice
Caroline Marty et al.
BLOOD (2010)
Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease
Hajime Akada et al.
BLOOD (2010)
JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia
Juan Li et al.
BLOOD (2010)
Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor Cells
Ann Mullally et al.
CANCER CELL (2010)
Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia
Andrea Hoelbl et al.
EMBO MOLECULAR MEDICINE (2010)
STAT5 Activation Is Critical for the Transformation Mediated by Myeloproliferative Disorder-associated JAK2 V617F Mutant
Megumi Funakoshi-Tago et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Conditional deletion of STAT5 in adult mouse hematopoietic stem cells causes loss of quiescence and permits efficient nonablative stem cell replacement
Zhengqi Wang et al.
BLOOD (2009)
Translation of the Philadelphia chromosome into therapy for CML
Brian J. Druker
BLOOD (2008)
Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice
Shu Xing et al.
BLOOD (2008)
Hematopoietic-specific Stat5-null mice display microcytic hypochromic anemia associated with reduced transferrin receptor gene expression
Bing-Mei Zhu et al.
BLOOD (2008)
Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice
Ralph Tiedt et al.
BLOOD (2008)
Targeting Ras in myeloid leukemias
Benjamin S. Braun et al.
CLINICAL CANCER RESEARCH (2008)
Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F
K. Shide et al.
LEUKEMIA (2008)
Elucidation of the phenotypic, functional, and molecular topography of a myeloerythroid progenitor cell hierarchy
Cornelis J. H. Pronk et al.
CELL STEM CELL (2007)
Molecular Pathogenesis and Therapy of Polycythemia Induced in Mice by JAK2 V617F
Virginia M. Zaleskas et al.
PLOS ONE (2006)
Characterization of murine JAK2V617F-positive myeloproliferative disease
Thomas G. P. Bumm et al.
CANCER RESEARCH (2006)
Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells
Loic Garcon et al.
BLOOD (2006)
STAT5 signaling is required for the efficient induction and maintenance of CML in mice
Dan Ye et al.
BLOOD (2006)
Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation
Andrea Hoelbl et al.
BLOOD (2006)
Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model
Gerlinde Wernig et al.
BLOOD (2006)
JAK2(V617F) expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis
Catherine Lacout et al.
BLOOD (2006)
Identification of an acquired JAK2 mutation in Polycythemia vera
RX Zhao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
EJ Baxter et al.
LANCET (2005)
Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations
MG Mohi et al.
CANCER CELL (2005)
Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease
IT Chan et al.
JOURNAL OF CLINICAL INVESTIGATION (2004)
Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder
BS Braun et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation
Y Cui et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Transgenic mice with hematopoietic and lymphoid specific expression of Cre
J de Boer et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2003)
vavCre transgenic mice:: A tool for mutagenesis in hematopoietic and endothelial lineages
P Georgiades et al.
GENESIS (2002)
Overexpression of a dominant negative form of STAT3 selectively impairs hematopoietic stem cell activity
IH Oh et al.
ONCOGENE (2002)
Critical role for Gab2 in transformation by BCR/ABL
M Sattler et al.
CANCER CELL (2002)
分享论文
